Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan + amoxicillin + sitafloxacin triple therapy as third-line H. pylori eradication
jRCTs031190031Active, not recruiting
- Sponsor
- Yokohama City University
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vonoprazan, amoxicillin and sitafloxacin in Helicobacter pylori infection, sponsored by Yokohama City University. Primary endpoint: Eradication rate. Started Jun 2019; status: active, not recruiting.
02
Drugs
vonoprazanamoxicillinsitafloxacin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on jRCTs031190031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190031.